premenstrual dysphoric disorder Tagged Articles
Off-label marketing boosts drug company profits
Off-label marketing is an illegal yet commonly employed sales strategy that some big pharmaceutical companies practice to broaden the appeal of a drug and boost sales. One of the most blatant examples of off-label marketing involved Bayer Healthcare’s blockbuster birth
Comedian lampoons the absurdity of drug ads
Writer-comedian Sarah Haskins has produced another segment of her popular satire on Current TV’s Target: Women, this time calling out the absurdity of television advertising in marketing drugs to women.
Injured by Yaz, SC nurse files lawsuit against Bayer
A 33-year-old nurse from South Carolina has filed suit against Bayer Healthcare Pharmaceuticals, charging that Yaz caused her multiple personal injuries. According to a report published by Reuters, the woman received a Yaz prescription from her dermatologist in March 2008
Switzerland investigates the death of young Yaz user
A Swiss health agency is investigating the death of a young woman in Switzerland who died while taking Bayer AG’s birth control pill Yaz. Bloomberg reported that Swissmedic (Switzerland’s drug therapy regulatory agency) and an investigative judge are probing the
Yaz health risks: better safe than sorry?
Bayer Healthcare’s blockbuster drug Yaz has come under fire in recent years for its potential to cause a spectrum of health problems. Bayer has downplayed these serious risks while drawing attention to some of the drug’s other uses as treatments
Yaz testing and marketing raises ethical red flag
A new report in the New York Times about Bayer Healthcare’s bestselling oral contraceptive Yaz brings to light some serious ethical questions surrounding the company’s testing and marketing of what some studies suggest is a potentially dangerous drug for many
Yaz lawsuits consolidated in Pennsylvania
Yaz and Yasmin lawsuits filed against Bayer Healthcare in Pennsylvania state courts were consolidated into a mass tort last week by Philadelphia Court of Common Pleas judge Sandra Mazer Moss, who appointed 3 Pennsylvania attorneys to serve as liaison counsel
Yaz ingredient not properly tested, FDA warns Bayer
The U.S. Food and Drug Administration has admonished German drug manufacturer Bayer for failing to test a vital ingredient used in Yaz and other birth control drugs according to American standards.
Bayer creates new ad campaign for Yaz after FDA crackdown
In October 2008, the U.S. Food & Drug Administration (FDA) sent a letter of warning to Bayer Healthcare, Inc., citing the drug manufacturer for misrepresentations in television commercials for Yaz, an oral contraceptive. The ads featured the usual women’s health
PMDD medication linked to Tardive Dyskinesia
Warner Chilcott, the makers of Sarafem (fluoxetine hydrochloride), a treatment for Premenstrual Dysphoric Disorder (PMDD), have issued a warning about the risk of neuroleptic malignant syndrome, also known as Tardive Dyskinesia, a condition in which a person develops involuntary movements
